ABOUT
YODEAH

OUR STORY

Ashkenazi Jewish men and women are more likely to carry hereditary genetic mutations that can significantly increase their lifetime risk of cancer. Most people do not KNOW and will not have a family history. Yodeah’s mission is to educate the Jewish community about hereditary cancer genetic mutations and provide access to affordable, clinical-grade testing. Yodeah’s goal is to save lives.

Knowledge is power. 

ELIZABETH ETKIN-KRAMER, M.D, F.A.C.O.G, FOUNDER

Dr. Etkin-Kramer has been a board-certified obstetrician/gynecologist in Miami Beach since 1993. She holds teaching positions at both FIU and University of Miami medical schools. She has a particular interest in breast and ovarian cancer risk assessment and has educated other healthcare providers on risk assessment inclusive genetic testing. As the scientific literature over the years has clearly shown that Ashkenazi Jews are more likely to inherit BRCA mutations regardless of family history, and most are unaware, she has been a vocal proponent of population-based genetic testing in the Ashkenazi Jewish community. She co-founded the Prevent Hereditary Cancer Coalition with Lauren Corduck (z”l) to identify carriers to mitigate hereditary cancer burden in those individuals and families.

OUR VOLUNTEERS

BOARD MEMBERS

Elizabeth
Etkin Kramer, M.D.
Caryn
Duboff
Sandy
Grossman

Lauren Harshman Davis, M.D.

Rabbi Laila Haas

Adrienne Pardo, Esq.

Caryn
Pardo

Gina Russ, Esq.

Robin Strauss Furlong, M.D.

Eileen Youtie z”l

MEDICAL ADVISORY BOARD

Line Bohbot,
PA-C
Danielle
Kramer, M.D.
Elisa
Krill-Jackson, M.D.

RABBINIC ADVISORY BOARD

Rabbi Laila Haas
(Chair)
Rabbi Jeremy
Barras
Rabbi Peter
Kasdan
Rabbi Dan
Levin

THANK YOU TO OUR SPONSORS FOR SUPPORTING YODEAH’S MISSION

THE MOST RELEVANT GENES FOR COMMON HEREDITARY CANCERS

* CDK4: analysis is limited to chr12:g.58145429-58145431 (codon 24). EPCAM: analysis is limited to deletions that minimally encompass the 3′ end of the gene including exons 8 and/or 9. GREM1: analysis is limited to duplications that overlap the upstream regulatory region. MITF: analysis is limited to chr3:g.70014091 (including c.952G>A). MUTYH: single heterozygous pathogenic variants, likely pathogenic variants, and variants of uncertain significance are not reported. PMS2: variants of uncertain significance are not reported for exons 12-15. Analysis excludes three variants commonly observed in the pseudogene PMS2CL: c.2182_2184delinsG, c.2243_2246delAGAA and deletion of exons 13-14 (chr7:g.6015768_6018727del). POLD1: analysis is limited to chr19:g.50909713 (including c.1433G>A). POLE: analysis is limited to chr12:g.133250250 (including c.1270C>G).